Seeking Alpha

Imprimis Pharmaceuticals acquires the intellectual property rights for ophthalmic compound from Novel Drug Solutions

  • Imprimis Pharmaceuticals (IMMY -4.7%) acquires the intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents from Novel Drug Solutions.
  • The target compound, referred to as IPI-140, is based on a combination of moxifloxacin and triamcinolone.
  • IMMY says it believes the formulation has the potential to "impact the fast-growing $5B global cataract surgery drug market."
  • Additionally, the deal gives IMMY preemptive rights to other Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs